Cancer patients have misconceptions about immunotherapy, expecting it to be a huge breakthrough in efficacy but with little or no knowledge about the toxicities, Australian research shows. According to a series of in-depth interviews with 29 Australian patients receiving pembrolizumab for their stage IV melanoma, hope is the key issue underpinning treatment decisions. Patients have ...
Patients have misconceptions about immunotherapy efficacy and toxicities
By Mardi Chapman
2 May 2019